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Abstract
The tyrosine kinase receptor Met and its ligand,
hepatocyte growth factor/scatter factor (HGF/SF), play
an important role in normal developmental processes,
as well as in tumorigenicity and metastasis. We con-
structed a green fluorescent protein (GFP)Met chimeric
molecule that functions similarly to the wild-type Met
receptor and generated GFP–Met transgenic mice.
These mice ubiquitously expressed GFP–Met in spe-
cific epithelial and endothelial cells and displayed en-
hanced GFP–Met fluorescence in sebaceous glands.
Thirty-two percent of males spontaneously developed
adenomas, adenocarcinomas, and angiosarcomas in
their lower abdominal sebaceous glands. Approxi-
mately 70% of adenocarcinoma tumors metastasized
to the kidneys, lungs, or liver. Quantitative subcellular-
resolution intravital imaging revealed very high levels
of GFP–Met in tumor lesions and in single isolated
cells surrounding them, relative to normal sebaceous
glands. These single cells preceded the formation of
local and distal metastases. Higher GFP–Met levels
correlated with earlier tumor onset and aggressive-
ness, further demonstrating the role of Met–HGF/SF
signaling in cellular transformation and acquisition
of invasive and metastatic phenotypes. Our novel
mouse model and high-resolution intravital molecular
imaging create a powerful tool that enables direct real-
time molecular imaging of receptor expression and lo-
calization during primary events of tumorigenicity and
metastasis at single-cell resolution.
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Introduction
The Met tyrosine kinase receptor and its ligand, hepatocyte
growth factor/scatter factor (HGF/SF), are essential for
embryonic development [1]. Met and HGF/SF are broadly
expressed in adult tissues and have been implicated in the
homeostasis of general physiological responses to tissue
damage (including liver, kidney, and heart injuries) and in angio-
genesis [1]. In addition, Met–HGF/SF signaling is involved in
altering the metabolic activity of cells by enhancing both the
glycolytic and the oxidative phosphorylation pathways [2,3].
Aberrant Met signaling has been widely implicated in most
types of human cancers (http://www.vai.org/metandcancer).
Met activation was also shown to play a role in the develop-
ment of tumors expressing both epithelial and mesenchymal
markers [4], and increased Met or HGF/SF expression often
correlated with poor prognosis [5–8]. There are several ways
by which Met can be activated in tumors: 1) autocrine signal-
ing, as found in osteosarcoma and glioblastoma multiforme
[9,10]; 2) paracrine signaling, as observed in carcinomas
expressing Met, with HGF/SF being present in the stromal en-
vironment [1]; and 3) activation of Met mutations, which were
originally discovered as germline mutations in families pre-
disposed to several carcinomas [11] and recently found in a
variety of cancers as sporadic mutations in the kinase, juxta-
membrane, and extracellular domains [11,12].
Overexpression of both ligand and receptor is associated
with several malignancies [13–15] and has been shown to be a
strong independent predictor of recurrence, decreased sur-
vival [5,16–18], and poor prognosis [6,7] (http://www.vai.org/
metandcancer). Met–HGF/SF signaling is also associated
with malignant progression and metastasis of a large number
of tumors, including human esophageal squamous cell carci-
nomas [19], prostate cancer [20], and ovarian cancer [21].
Met and HGF/SF display tumorigenic activity in a number of
animal models. Transgenic Met expression in mice generates
tumors such as hepatocellular carcinomas [22], whereas ex-
pression of mutationally activated Met receptors in transgenic
and knockin mice leads to the onset of a wide range of tumors,
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including carcinomas and lymphomas [12,23]. Mice express-
ing anHGF/SF transgene in a tissue-specificmanner display a
wide variety of tumors, including melanomas, schwannomas,
rhabdomyosarcomas, hepatomas, andmammary carcinomas
[24,25], some of which develop metastases [26]. The tumors
showhigh expression of theHGF/SF transgene and enhanced
Met kinase activity. Overexpression of HGF/SF also induces
severe developmental and functional abnormalities [24,27,28].
Recently, fluorescent proteins have been recruited into
cancer research. Green fluorescent protein (GFP) has been
used for detecting and tracking specific cancer cell lineages
during tumor development [29–31] and has been coupled
to proteins to follow their localization [32]. In this article, we
describe a unique GFP–Met transgenic mouse model and
a novel high-resolution intravital molecular imaging modal-
ity. Our results establish the first animal model that allows
direct subcellular-resolution imaging of expression patterns
of tyrosine kinase growth factor receptor in live animals. We
show here that GFP–Met is responsible for the develop-
ment of GFP–Met tumors and that following its expression
enables the detection of transformed sebaceous glands
and single cells outside the tumors that may be the precur-
sors of local and distal metastases. Together, high-resolution
imaging and our animal model may be used for studying
the cellular and molecular mechanisms of tumorigenicity and
metastasis, and for understanding the inhibitory effects and
efficacy of Met-targeted cancer therapeutics in vivo.
Materials and Methods
Plasmid Construction and Generation of Transgenic Mice
The coding sequence of Met was amplified using the
pr imers 5 V-CGTAGGTACCATGAAGGCTCCCACC-
GTGCTG-3V and 5V-TAGTGGATCCGTGTTCCCCTCGC-
CATCAAT-3V, which contain KpnI and BamHI restriction
sites, respectively, at their 5V ends. Met cDNA was cloned
into the pEGFP-N1 vector (Clontech Laboratories, Mountain
View, CA). To eliminate any mutations within the Met ampli-
fied coding region, a fragment of 3719 bp was digested out
usingBstXI restriction enzyme andwas replacedwith a 3719-
bp BstXI fragment from pMB11 [33] to create pGFP–Met.
The remaining amplified fragments were confirmed by se-
quencing. pGFP–Met plasmid was digested out of pGFP–
Met, purified, and injected into mouse oocytes. GFP–Met
transgenic founders were generated, as confirmed by poly-
merase chain reaction (PCR) analysis of the tail DNA. PCR
amplification of GFP–Met was carried out using the following
primers: 5V-TGTGCTCCTCTGGGAGCTCATGACGA-
GAGG-3V and 5V-CACTGCACGCCGTAGGTCAGGGTGGT-
CACG-3V. Positivemice were identified by the amplification of
a 0.5-kb DNA fragment. Experiments using mice were ap-
proved by the Van Andel Research Institute Institutional
Animal Care and Use Committee.
Confocal Laser Scanning Microscopy (CLSM) Imaging
All confocal analyses were carried out using an LSM 510
META (Zeiss, Jena, Germany) confocal laser scanning mi-
croscope with the following configurations: 25-mW krypton/
argon (488, 514, and 568 nm) and HeNe (633 nm) lasers,
and a Ti-sapphire tunable pulse laser. To overcome the
problem of high background fluorescence signals from an
intact live mouse or an intact organ, spectral analysis was
performed using a META detector. To isolate GFP fluores-
cence, lambda unmixing algorithm was used.
Intravital imaging of live mice was carried out using the
above CLSM system. Mice were anesthetized with isoflurane
(2.5% in oxygen), hair from the imaged area was removed
using a depilatory cream, and the anesthetized mouse was
placed on the microscope stage and kept anesthetized
while being imaged. To avoid GFP signal reduction, frozen
sections of different tissues were imaged unfixed using the
META detector and the lambda unmixing algorithm.
Image analysis of average fluorescence intensity per
square micrometer was carried out using MICA image analy-
sis software (Cytoview LTD, Petach Tikva, Israel). The statis-
tical difference in average area intensity in the different mice
groups was calculated either by Student’s t test or by analysis
of variance using Microsoft Excel software (Microsoft, Red-
mond, WA).
Fluorescence-Activated Cell Sorter (FACS) Analysis
Blood samples were obtained by cardiac puncture. Sam-
ples were treated with red blood cell lysing buffer (R7757;
Sigma-Aldrich, St. Louis, MO) in accordance with the manu-
facturer’s instruction, washed thrice with phosphate-buffered
saline (PBS), and subjected to FACS analysis.
Pathological Analyses
Tissues were immersion-fixed in neutral-buffered formalin
overnight and processed in a graded series of solutions.
Fixed tissues were dehydrated, embedded in paraffin, cut
into 5-mm sections, and stained with hematoxylin and eosin
(H&E). Histology and histopathology were characterized
using standard anatomic pathology classifications and de-
scriptions by two independent histopathologists. Diagnoses
were recorded and incorporated into the data set for each
animal and lesion.
Immunofluorescence Staining
Fixed sections were deparaffinized and blocked (5%
bovine serum albumin and 10% normal donkey serum in
PBS) for 30 minutes at room temperature. Slides were then
incubated with anti-GFP antibody overnight at 4jC. After
three washes in PBST (0.05% Tween 20 in PBS), cells were
stained with either donkey anti-rabbit or anti-mouse antibody
conjugated to either Texas Red or FITC (Jackson Immuno
Research Laboratories, West Grove, PA) for 1 hour at room
temperature in the dark. Slides were washed thrice in PBST
and mounted with cover slips using GelMount (Biomeda,
Foster City, CA). Immunostained sections were analyzed
using the 510 Zeiss CLSM described above.
Western Blot (WB) Analysis and Immunoprecipitation (IP)
For biochemical experiments, tissues were homogenized
in 0.4 ml of lysis buffer [20 mM Tris–HCl, pH 7.8, 100 mM
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NaCl, 50 mM NaF, 1% NP40, 0.1% sodium dodecyl sulfate
(SDS), 2 mM EDTA, and 10% glycerol] containing protease
inhibitor cocktail (Roche Molecular Biochemicals, Man-
nheim, Germany) and 1 mM sodium orthovanadate. Cell
lysates were clarified by centrifugation, and protein concen-
tration was quantified using a BCA protein assay kit (Pierce,
Rockford, IL). For IP, 500 mg of total protein was adjusted
to a volume of 500 ml using a lysis buffer, and 5 ml of B2 anti-
Met monoclonal antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) was added to each sample. Samples were
incubated for 2 hours on ice, with occasional mixing. To pre-
cipitate antibody–Met complexes in the mixture, 50 ml of
50% protein G beads slurry (Amersham Biosciences, Up-
psala, Sweden) was added to the mixture, and the samples
were incubated in an inverting rotator for 2 hours at 4jC. The
beads were then pelleted, washed thrice in a lysis buffer,
and resuspended in 50 ml of 2 SDS loading buffer for gel
electrophoresis. Samples were separated by SDS poly-
acrylamide gel electrophoresis and transferred onto a PVDF
membrane (Invitrogen Life Technologies, Carlsbad, CA).
Visualization was achieved using horseradish peroxidase–
conjugated anti-mouse IgG, electrochemiluminescence re-
action, and exposure to X-ray film (Kodak, Rochester, NY).
On several occasions, the same membrane was subjected
to several consecutive experiments following stripping with
a fresh solution of Ponceau S (0.2% in 3% trichloroacetic
acid in H2O).
Ultrasound Analysis
Mice were monitored for tumor appearance once a week
by palpation. Tumor size was measured by ultrasonography.
Sonography was performed using a 15L8 linear transducer
(15 MHz, Acuson Sequoia 512; Acuson, Mountain View,
CA). Mice were anesthetized using isoflurane (oxygen
flow, 1 l/min; isoflurane vaporizer up to 2%). Before sonog-
raphy, hair in the tumor area was removed using a thin layer
of Nair (Carter Product, New York, NY). A warm-water
heating pad was used to avoid hypothermia during imaging.
Gray-scale sonography was performed on days 0, 7, 14, and
21 after tumor palpation. Each animal was evaluated for
tumor presence, size, and location. Imaging settings were
standardized and were not changed throughout the ex-
periment. No major near-field artifacts were encountered.
Images were obtained by experienced sonographers who
were blinded to the experiment. In vivo ultrasound experi-
ments were performed in triplicate, showing similar results.
Results
pGFP–Met Construction and Activity
We generated a GFP–Met construct by fusing GFP to the
C-terminus of murine met cDNA in the pGFP-N1 vector
(pGFP–Met). To test GFP–Met expression, subcellular locali-
zation, and activation, we transiently transfected pGFP–Met
into 293T cells and compared them to 293T cells transfected
with mouse met. IP using anti-Met antibody, followed by
immunoblotting (IB) with anti-Met antibody, displayed the
classic 170- and 140-kDa mouse Met bands (Figure 1A) from
293T cells transfected with met, whereas GFP–Met–trans-
fected cells displayed two bands at 200 and 170 kDa, which
are the precursor andmature forms ofGFP–Met, respectively,
showing the additional 27 kDa of the GFP tag. Western blot
analysis of pGFP–Met–transfected cells using anti-GFP anti-
bodies revealed high levels of 200- and 170-kDa proteins
(Figure 1B), whereas cells transfected with pGFP-N1 vector
alone produced only a 27-kDa GFP band. These analyses
validate that the 200- and 170-kDa proteins are GFP–Met.
Subcellular localization of GFP–Met was analyzed using
the CLSM of transiently transfected 293T cells. GFP–Met
signal was localized to the cell membrane (Figure 1C) in the
pattern expected of an endogenous Met receptor [34]. Fluo-
rescent signals were not detected in pMet-transfected 293T
cells (Figure 1D), and GFP alone was distributed to the
cytoplasm (data not shown).
We also tested whether GFP–Met retained endogenous
biologic activities. GFP–Met activity was compared to Met
activity in 293T transiently transfected cells. Cell lysates
were subjected to IP with anti-Met and IB using anti–
phosphorylated tyrosine (Figure 1E ), anti–phosphatidyl ino-
sitol 3 kinase (PI3K) (Figure 1F ), or anti-Grb2 (Figure 1G)
antibodies. GFP–Met biologic function was retained in all
tested signal transduction pathways. No significant decrease
Figure 1. GFP–Met retains Met biologic function and localization. The
characterization of the transient expression of GFP–Met was carried out in
293T cells transiently transfected with pGFP–Met plasmids. Nontransfected,
pMet-transfected, or pGFP-N1– transfected 293T cells served as controls. (A)
IP and IB analyses of 293T cells transiently expressingGFP–Met, GFP, orMet
using anti-GFP antibodies (IP) and anti-Met antibody (IB). (B) WB analysis of
GFP–Met, GFP, and Met transient expression in 293T cells with anti-GFP
antibody. CLSM fluorescence analysis of GFP–Met (C) and Met subcellular
localization (D). Size bars, 20 m. IP and IB analyses of 293T cells transiently
expressing GFP–Met or Met in the presence (+) or absence () of HGF/SF.
Cells were lysed and subjected to IP andWB analyses (E, F, & G). IP with anti-
pTyr antibody and IB using anti-Met (E), IP with anti-Met and IB using anti-PI3K
(F), or IP with anti-Met and IB using anti-Grb2 (G).
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in its activity was observed, compared with Met. A minor
effect on activity was observed in lower tyrosine phosphory-
lation levels on HGF/SF treatment (Figure 1E ) and lower
co-IP levels of both PI3K (Figure 1F ) and Grb2 (Figure 1G).
These results demonstrate that GFP–Met is biologically
functional and that the GFP tag does not interfere with its
signal transduction.
GFP–Met Expression in Transgenic Mice
We generated transgenic mice expressing GFP–Met
from the CMV promoter using the pGFP–Met construct de-
scribed above. Five founders were used in this study because
differences between independent transgenic mouse lines
and between different tissues expressing a reporter gene
from the CMV promoter have been reported [35,36].
To image GFP–Met expression in vivo, we developed
real-time high-resolution quantitative intravital molecular
imaging using CLSM (see the Materials and Methods sec-
tion). Imaging of transgenic mice revealed high expression
levels of GFP–Met in sebaceous glands (Figure 2A). High
levels of GFP–Met were observed on the cell membrane of
sebaceous cells, revealing the overall three-dimensional
structure of the gland at a very high resolution. Control non-
transgenic mice showed only marginal background levels
of green fluorescence (Figure 2A, inset). Quantitative analy-
sis of fluorescence levels from 254 sebaceous glands
showed variations between different founders (Figure 2B).
Overall, GFP–Met transgenic mice showed in vivo higher
fluorescence levels in their sebaceous glands relative to
levels in the sebaceous glands of control nontransgenic
mice. In three of the founder lines (975, 987, and 988), fluo-
rescence was high; in two (928 and 958), fluorescence was
moderate (Figure 2B) (P = .0035).
Analysis of GFP–Met expression in different organs
shows high levels in the spleen, kidneys, and skin; moderate
levels in the liver; low levels in the lungs; and marginal levels
in the brain (data not shown), suggesting that GFP–Met is
ubiquitously expressed in this transgenic mice model.
Overexpression of GFP–Met Induces Tumor Development
in Transgenic Mice at an Early Age
GFP–Met transgenic male mice developed spontaneous
tumors in the sebaceous glands of their lower abdominal skin
area above the gonads (Figure 3B). The masses were not
observed in female mice even at an older age (up to 2 years).
Tumors were pale or red, round and lobular in appearance,
and grew rapidly once they were palpable. The tumors were
0.5 to 0.8 cm in diameter when they ruptured, releasing
sebaceous or pus-like sebum/liquid. Tumor development
was observed in 32 ± 3.6% of male mice (Figure 3A, gray
bars) at an average age of 6.9 ± 3.01 months (Figure 3B,
white bars). Tumor onset was detected between 1.5 and
16 months of age. Early tumor onset positively correlated
with GFP–Met expression levels (Figure 3A). Founder lines
with high GFP–Met expression (975, 987, and 988) de-
veloped tumors earlier than lines with moderate expression
(928 and 958) (average age of 6.1 and 10.7 months, re-
spectively; P = .0015).
To substantiate the hypothesis that tumor development in
the sebaceous gland correlates with high levels of GFP–
Met, we performed comparative intravital CLSM analyses
of normal and transformed sebaceous glands. Intravital op-
tical molecular imaging of sebaceous glands in the lower
abdominal area revealed increased expression levels in
transformed sebaceous glands (n = 11) compared with
normal glands of both male and female mice (n = 23 and
n = 21, respectively; Figure 3C). GFP–Met levels were 1.83
times higher in neoplastic glands than in normal male seba-
ceous glands, and were 1.78 times higher (P = 2.33  1011)
in male than in female transgene sebaceous glands of the
distal ventral abdominal area. These results further demon-
strate a positive correlation between high GFP–Met levels
and tumorigenic phenotype.
Pathological analyses ofGFP–Met tumors revealed hyper-
proliferative sebaceous gland tumors that were identified
mainly as adenomas, adenocarcinomas, and angiosarcomas
(Figure 3D). H&E staining of the secreted material revealed
no cells but a puss-like degraded necrotic substance (data
not shown).
Control transgenic mice, expressing only GFP from a tie-2
promoter, demonstrated a wide range of tissue expressions,
including those in the sebaceous glands (data not shown).
However, no phenotype was evident, suggesting that GFP
itself is not responsible for tumor formation in the sebaceous
glands in GFP–Met transgenic mice.
Figure 2. GFP–Met transgenic expression in mice. (A) In vivo imaging of a
sebaceous gland from a GFP–Met transgenic mouse. GFP–Met expression
can be detected on the cell membrane of single cells in the gland (indicated by
arrowheads). The inset shows an image from a nontransgenic mouse at the
same conditions. Size bars, 20 m. (B) Quantitative analysis of the fluo-
rescence/area obtained from five different founder lines of GFP–Met trans-
genic mice. Each bar represents at least five mice (10 images per mouse).
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Imaging Early Events of Metastasis
Intravital optical molecular imaging of tumor areas
revealed single cells spreading from the tumor and express-
ing high GFP–Met levels (Figure 4, A and B) relative to sur-
rounding normal tissues. Such single cells were not detected
around normal sebaceous glands (data not shown). To
further monitor GFP–Met expression in sebaceous gland
tumors, CLSM of excised and frozen tumor sections was
performed. Close examination of intact excised tumors re-
vealed single cells expressing high levels of GFP–Met in
patches on the cell surface (Figure 4C). Imaging of unfixed
frozen sections of tumors revealed a large number of cells
Figure 3. Male GFP–Met transgenic mice develop sebaceous gland tumors. (A) Tumor occurrence rate (dark bars) and age of tumor onset (white bars) according
to founder lines (928, 958, 975, 987, and 988; n = 22, 21, 91, 50, and 63, respectively). (B) Sebaceous gland tumors spontaneously develop in the lower abdominal
area of male GFP–Met transgenic mice. (C) Quantitative analysis of the fluorescence/area of normal sebaceous glands obtained from males and females (M and
F, respectively) relative to transformed (T) glands. Each bar represents at least five mice (10 images per mouse). (D) H&E staining of sebaceous gland tumors:
normal skin (N), adenoma (Ad), angiosarcoma (AnSa), and adenocarcinoma (AdCa).
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overexpressing GFP–Met (Figure 4D). These cells were
absent in frozen sections of normal tissues (data not shown).
Transgenic GFP–Met mice harboring tumors with or
without metastasis were screened for single metastatic cells
with high fluorescence in their blood, using FACS analysis of
1  106 cells after red blood cells lysis (see Materials and
Methods section). GFP–Met mice that did not develop
tumors served as negative controls. Single cells expressing
high levels of GFP–Met were isolated from blood samples
of mice harboring a tumor and demonstrating metastasis
(1371 per 1  106 cells). A significantly lower number was
obtained from GFP–Met tumor-bearing mice that did not de-
velop metastasis (481 per 1  106 cells), and only 210 fluo-
rescent cells were counted in mice not harboring tumors. A
detailed analysis of the cells’ fluorescence levels revealed
that cells originating from mice harboring a tumor and
demonstrating metastasis exhibited high fluorescence
levels (data not shown), whereas cells originating from
mice without a tumor demonstrated significantly lower fluo-
rescence levels. Confocal microscope analysis of the cells
showed a typical membrane-bound GFP–Met fluorescence.
Cells obtained from mice bearing primary tumors showed
only moderate levels of fluorescence in the blood. These re-
sults indicate that single cells expressing high levels of
GFP–Met could be detected in vivo, in excised tumors,
and in the blood of mice bearing tumors and demonstrat-
ing metastases.
Immunohistochemical analysis of fixed GFP–Met tumors
and their margins was carried out using anti-GFP antibodies.
GFP–Met staining was strong in tumor regions, with in-
creased levels in peripheral areas (Figure 5, A and C).
Normal skin tissues surrounding the tumor showed only
marginal GFP–Met levels. Within tumor margins, single
cells expressing high levels of the receptor were detected
(Figure 5, A and C). Close examination of H&E staining
(Figure 5B) revealed that these cells had prominent nuclei
and relatively abundant amphiphilic cytoplasm consistent
with anaplastic or neoplastic alterations. These individual
cells appear morphologically similar to GFP–Met tumor cells
(Figure 5B). We were also able to detect local micro-
metastases of GFP–Met tumors (Figure 5C). H&E staining
of the area revealed a clump of cells that are plumper and
more amphiphilic than surrounding mesenchymal cells, sug-
gesting that these cells have altered growth consistent with
neoplasia (Figure 5D). Vascularization adjacent to this cell
clump is evident in H&E staining. Importantly, GFP–Met
molecular imaging allowed the identification of these meta-
static cells in what was analyzed as normal surrounding
tissues in H&E sections (Figure 5, B and D). This finding
further supports the observation made by others that tissues
surrounding a primary tumor commonly contain transformed
cells with metastatic potential [37].
In addition, we compared the fluorescence levels of tu-
mor cells, normal cells, and single metastatic cells in tumor
Figure 4. Imaging single cells expressing GFP–Met. Single cells expressing high levels of GFP–Met could be detected in close proximity to the tumor by intravital
imaging at low (A) and high (B) magnifications. Single cells expressing high levels of GFP–Met in patches on their cell surface were also imaged in excised intact
tumors (C), as well as in unfixed frozen sections of sebaceous gland adenocarcinomas (D). Size bars, 20 m.
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margins from four different mice. Tumor cells and single
metastatic cells appeared to exhibit similar high florescence
levels (4.3- and 3.4-fold, respectively) compared with normal
tissue fluorescence (normalized to 1.0), suggesting that
these highly fluorescent cells are single metastatic cells.
Follow-Up of Tumor Development in GFP–Met
Transgenic Mice
Tumor size and anatomic progression were followed
in vivo by ultrasound imaging. Tumors were imaged weekly
starting at the early stages of tumor palpation. GFP–Met
tumors grew rapidly from 180 to 270 mm3 (Figure 6A, a and
b) and then ruptured, resulting in decreased size (144 mm3;
Figure 6Ac), followed by the observation of local metas-
tases in close proximity to the original tumor (Figure 6Ad ).
Single cells that were detected by CLSM around the tumor
(Figure 5) may be the precursors of these local metas-
tases. Pathological analysis was performed on 40 mice.
The majority of tumors were malignant and were identified
as adenocarcinomas (42.5%), angiosarcomas (27.5%), or
poorly differentiated nonidentified tumors (10%); the minority
(20%) were benign adenomas (Figure 6B). Thirty-five per-
cent of GFP–Met transgenic mice that developed tumors
also developed metastases. Metastases were found locally
in the skin and in distant organs such as the liver, lungs, and
kidneys. Pathological analyses revealed sebaceous gland
adenocarcinoma morphology in 70.6% of metastases and
angiosarcomas in 18.2% of metastases (Figure 6B).
Biochemical analysis of the levels of GFP–Met precursor
(p200) and processed (p170) forms was performed in normal
and transformed sebaceous glands (Figure 6C). GFP–Met
levels increase gradually from low in normal skin, to moder-
ate in adenoma and angiosarcoma, and to high in adeno-
carcinoma—the most aggressive tumor in our model (70.6%
of metastases). These results demonstrate a positive corre-
lation between GFP–Met levels and tumor aggression.
To further validate the high GFP–Met levels observed in
tumors relative to normal sebaceous glands, we performed
immunostaining on multiple sections of normal and seba-
ceous gland tumors (33 and 31 sections, respectively) in a
GFP–Met tissue array using anti-GFP antibody. GFP–Met
expression level was significantly elevated in the tumors
(Figure 7, C and D) relative to normal skin (Figure 7, A
and B). Quantitative analysis of fluorescence levels, normal-
ized per area, was performed (Figure 7E; n = 64, P = 8.6 
1012). The average GFP–Met level in tumors appeared to
be three times higher than the average level in normal skin
samples of the same mice. Similar results were obtained
with anti-pTyr antibody. A 2.72-fold increase in tyrosine
phosphorylation was observed in tumors relative to normal
tissues (data not shown), indicating that Met and its sub-
strates are phosphorylated and activated. To avoid misinter-
pretation of results, fluorescence levels were measured in
normal sebaceous glands and tumor areas only, defined as
a region of interest in the MICA image analysis software.
Our results indicate significantly higher GFP–Met levels in
Figure 5. Imaging tumor margins. Immunostaining with anti-GFP antibody and H&E staining of fixed adenocarcinoma sections. (A) Immunostaining of single cells
expressing high levels of GFP–Met in tumor margins. (B) H&E staining of the same area shown in (A). An arrow marks single cells in the two sections. (D)
Immunostaining of micrometastasis in tumor margins. (E) H&E staining of the same area shown in (D). Arrows indicate the area with single cells/micrometastasis
expressing high levels of GFP–Met. Size bars, 50 m.
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tumor cells than in normal sebaceous gland cells, further
demonstrating the major role of Met in tumorigenesis.
Discussion
AberrantMet–HGF/SF–Met signaling plays a significant role
in the pathogenesis of many types of solid tumors and other
malignancies. The abnormal expression of Met and HGF/SF
in most types of human cancer is associated with poor clini-
cal outcome [1]. To better understand the primary events of
tumorigenesis and metastasis, we have used transgenic
mice, in combination with molecular imaging, as our model
system. In this study, we show that transgenic mice ex-
pressing GFP–Met develop distinct neoplasms in male mu-
rine sebaceous glands. These tumors developed in all five
independent transgenic lines and included adenoma, adeno-
carcinoma, and angiosarcoma histopathology. Some malig-
nant lesions developed metastases to the lungs, kidneys,
and liver. Spontaneous occurrence of sebaceous tumors, as
observed in our animals, is rare in wild-type mice. We have
shown that GFP–Met levels are higher in transformed seba-
ceous glands and that there is a positive correlation be-
tween GFP–Met levels and both age of tumor onset and
tumor aggressiveness. Our results strongly suggest that, in
this transgenic model, tumors developed as a direct effect
of high GFP–Met expression levels, indicating that these
high levels are essential for tumor development. GFP is not
responsible for this spontaneous tumor development be-
cause transgenic GFP expression in mice did not yield any
sebaceous gland tumor. This is consistent with other works
in which a number of GFP-expressing transgenic mice
have been produced with no reported malignant pheno-
type [38–41]. Higher expression levels of Met in the tumors
were not observed in Met transgenic breast cancer models
[42]. Our results clearly demonstrate that higher levels of
GFP–Met produce cellular circumstances that support
tumor development.
Met overexpression in breast cancer has been reported in
a large number of studies [1]. A positive correlation between
Met levels and tumor aggressiveness on patients was dem-
onstrated in primary breast cancers and their lymph node
metastases. High Met levels in node-positive breast cancer
patients correlated with poor clinical outcome, independent
of Her2/neu [8]. Our results here further validate Met over-
expression in human malignancies as an important player
in tumorigenesis and metastasis. In this study, we observed
higher levels of GFP–Met expression in tumor tissues rela-
tive to corresponding normal tissues. Previous studies have
shown that increased Met levels could result either from
transcriptional upregulation or from increased protein stabi-
lization. Elevated met mRNA levels, accompanied by in-
creased protein levels, have been reported in human lung
adenocarcinoma cells [43] and human breast tumors [44].
However, because GFP–Met is driven by the CMV promoter
rather than the endogenous Met promoter, it is reasonable
to assume that higher GFP–Met levels in the tumor are due
to protein stabilization. The ubiquitin–proteasome pathway
is known to play a significant role in Met degradation and
may be important for averting cellular transformation [12]. In
the future, protein turnover in normal and tumor tissues will
be examined to determine the basis of increased GFP–Met
tumor levels.
The gradual increase in GFP–Met levels from normal
skin, to adenoma and angiosarcoma, to adenocarcinoma, as
demonstrated here, correlates with tumor progression. We
hypothesize that, during the physiological development of
sebaceous glands, cells expressing high GFP–Met levels
propagate and form foci of transformed cells within the gland.
Figure 6. GFP–Met sebaceous gland tumor progression. (A) Sebaceous
gland tumors were monitored weekly (a–d) using ultrasound imaging. Tumor
size was measured. Two new local metastases developed on week 4 (d).
Tumors are indicated by arrows. Size bars, 1 cm. (B) Histopathology of the
tumors revealed them to be adenomas (Ad), adenocarcinomas (AdCa), a
combination of adenomas and adenocarcinomas (AdCa + Ad), angio-
sarcomas (AnSa), or poorly developed nonidentified (NI) tumors. The per-
centage of each subtype is shown by gray bars; the percentage of metastatic
tumors is shown by open bars. Thirty-five percent of the tumors also develop
metastases; most of those were identified as adenocarcinomas. (C) WB
analysis of GFP–Met IP from homogenized tissue cell lysates of normal skin
(N), adenoma (Ad), adenocarcinoma (AdCa), and angiosarcoma (AnSa). A
cell lysate of pGFP–Met– transformed 293T cells serves as a positive control
(+). GFP–Met levels increase gradually from low in normal skin, to moderate
in adenoma and angiosarcoma, to high in adenocarcinoma.
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Gender and organ specificity of tumor development were
observed in all five GFP–Met founder lines independently.
The molecular mechanisms underlying this specificity are
not fully understood. A paracrine loop between stromal
compartments of the hair follicle (expressing HGF/SF) [45]
and GFP–Met in adjacent sebaceous glands may con-
tribute to organ specificity. The involvement of androgens
in GFP–Met tumor development, resulting from crosstalk
between Met–HGF/SF signaling and androgen receptor–
testosterone complexes, has been already suggested in sev-
eral studies [46–48]. Crosstalk between androgen- and HGF/
SF-activated signaling pathways is considered to be the re-
sult of interactions between transcription factors that regu-
late gene expression, resulting in a synergistic effect in the
growth stimulation of prostate epithelial cells [49]. The devel-
opment of sebaceous gland tumors adjacent to the male
gonads suggests that sex hormone dependency may play a
role in this animal model, particularly because there is a 25%
incidence of sebaceous carcinomas in the region of the ex-
ternal genitalia [50]. The role of androgen involvement and
gender specificity will be further studied in our laboratory.
GFP–Met– induced sebaceous tumors raise the question
of the possible involvement of Met in human sebaceous
gland tumors. As in our model, human neoplasms of the se-
baceous glands may be benign (sebaceous hyperplasia or
sebaceous gland adenomas) or malignant. Malignant human
sebaceous gland carcinomas also have organ preference
and are common in the head and neck, but mostly in the
eyelids (75%). These tumors tend to grow in nests with
central necrosis, resembling the appearance of GFP–Met
tumors. Similarly, they produce both local and distal metas-
tases. In addition, histopathological analyses reveal strong
similarity between these mouse and human malignancies. In
contrast to the GFP–Met mouse model, women (67%) have
a higher occurrence rate of sebaceous gland carcinomas
than men (http://www.emedicine.com/oph/topic716.htm).
The role of Met in human sebaceous gland carcinoma has
not been studied, and the molecular mechanisms involved
in human sebaceous gland transformation are not clear,
except for overexpression of nuclear p53 and expression of
c-erbB-2 oncoprotein in a small number of cases [51,52].
Taken together, these results show that our transgenic mice
may serve as an animal model for studying human seba-
ceous gland carcinoma.
Tumor metastasis is a highly selective process that
involves a large number of regulatory mechanisms. The
process begins with the detachment of cells from the primary
tumor by disruption of cell–cell interactions, which permits
the migration of tumor cells away from the primary tumor
[53]. Successful formation of metastases also requires
angiogenesis in the primary tumor site, followed by increased
tumor cell motility, which results in invasion into the new
vessels and tumor cell embolism [54]. The role of HGF/SF in
reducing the aggregation of tumor cells and in facilitating dis-
sociation and scattering has been demonstrated in breast
carcinoma and other malignancies [55]. To elude apoptotic
elimination, neoplastic cells must display a versatile set of ad-
hesive receptors by either expression or functional activation
20 μm
Figure 7. GFP–Met expression in normal skin and sebaceous gland tumors. GFP–Met levels were assessed in tumor and normal sections by immunostaining
using anti-GFP antibody. (A) H&E staining of normal skin. Size bar, 50 m. (B) Immunostaining of normal GFP–Met mouse skin from (A). Size bar, 20 m. (C) H&E
staining of GFP–Met sebaceous gland adenocarcinoma. Size bar, 50 m. (D) Immunostaining of the tumor in (C). Size bar, 20 m. (E) Quantitative analysis of
GFP–Met normal and tumor expressions from normal and tumor samples (P = 8.6  1012). N, normal sebaceous glands; T, tumors.
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of integrins. Upregulation of integrin transcription, as well as
integrin aggregation and activation, was demonstrated to be
induced by Met–HGF/SF signaling [55]. In addition, matrix
metalloproteases (MMPs), which localize and concentrate
matrix digestion at sites of directional cell invasion, can
selectively cleave extracellular matrix components to facili-
tate cell migration [56]. HGF/SF plays an important role in the
regulation of MMP-mediated proteolysis by both enhancing
the transcriptional levels of a large number of MMPs and
stimulating the conversion of their precursor forms into active
enzymes [55]. We describe the imaging of single cells that
express high levels of GFP–Met and spread from the tumor.
We hypothesize that these single cells are early precursors of
the metastasis of GFP–Met tumors.
In this paper, we present a novel approach for imaging the
early events of tumorigenesis and metastasis by using high-
resolution intravital optical molecular imaging to detect and
follow GFP–Met expression. An important benefit of molec-
ular imaging assays is their quantitative nature, as well as
their ability to depict three-dimensional information regarding
the spatial distribution of a particular protein in a particular
cell/organ or throughout the entire body in a living animal
[57]. Here, we demonstrate the ability of confocal intravital
molecular imaging to directly detect and quantify tyrosine
kinase receptor expression at subcellular resolution.
Our results establish GFP–Met transgenic mice as the
first animal model to enable direct single-cell resolution imag-
ing of tyrosine kinase growth factor receptor expression pat-
terns in a live animal. Such high-resolution modalities may be
crucial for understanding the cellular and molecular mecha-
nisms of tumorigenicity and metastasis, and for evaluating
inhibitory mechanisms and the efficacy of cancer therapeu-
tics in preclinical trials.
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